Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC1569 | HER2amp | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 200 | uM | 7448.084 | 0.8580 | 0.8944 | 2.8225 | |
| HCC1569 | HER2amp | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1000 | uM | 7448.084 | 0.0108 | -0.5975 | 2.8225 | |
| HCC1569 | HER2amp | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.00256 | uM | 7449.084 | 0.9285 | 0.9319 | 2.1410 | |
| HCC1569 | HER2amp | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.0128 | uM | 7449.084 | 0.9644 | 0.9664 | 2.1410 | |
| HCC1569 | HER2amp | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.064 | uM | 7449.084 | 0.9384 | 0.9415 | 2.1410 | |
| HCC1569 | HER2amp | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.32 | uM | 7449.084 | 0.9381 | 0.9412 | 2.1410 | |
| HCC1569 | HER2amp | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1.6 | uM | 7449.084 | 0.9685 | 0.9703 | 2.1410 | |
| HCC1569 | HER2amp | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 8 | uM | 7449.084 | 0.9454 | 0.9483 | 2.1410 | |
| HCC1569 | HER2amp | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 40 | uM | 7449.084 | 0.9144 | 0.9181 | 2.1410 | |
| HCC1569 | HER2amp | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 200 | uM | 7449.084 | 0.4324 | 0.3520 | 2.1410 | |
| HCC1569 | HER2amp | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1000 | uM | 7449.084 | 0.6056 | 0.5824 | 2.1410 | |
| HCC1806 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.00256 | uM | 7450.084 | 1.0517 | 1.0435 | 2.3432 | |
| HCC1806 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.0128 | uM | 7450.084 | 1.0874 | 1.0728 | 2.3432 | |
| HCC1806 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.064 | uM | 7450.084 | 1.0493 | 1.0415 | 2.3432 | |
| HCC1806 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.32 | uM | 7450.084 | 0.9432 | 0.9507 | 2.3432 | |
| HCC1806 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1.6 | uM | 7450.084 | 1.0296 | 1.0250 | 2.3432 | |
| HCC1806 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 8 | uM | 7450.084 | 0.9845 | 0.9867 | 2.3432 | |
| HCC1806 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 40 | uM | 7450.084 | 0.9724 | 0.9763 | 2.3432 | |
| HCC1806 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 200 | uM | 7450.084 | 0.5120 | 0.5029 | 2.3432 | |
| HCC1806 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1000 | uM | 7450.084 | 1.4104 | 1.3161 | 2.3432 | |
| HCC1806 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.000853 | uM | 7451.085 | 0.8809 | 0.8852 | 2.1458 | |
| HCC1806 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.00427 | uM | 7451.085 | 0.9655 | 0.9676 | 2.1458 | |
| HCC1806 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.0213 | uM | 7451.085 | 0.9502 | 0.9529 | 2.1458 | |
| HCC1806 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.107 | uM | 7451.085 | 0.9668 | 0.9688 | 2.1458 | |
| HCC1806 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.533 | uM | 7451.085 | 0.9863 | 0.9872 | 2.1458 |